Cantor Fitzgerald analyst Steven Halper lowered the firm's price target on Health Insurance Innovations to $75 from $80 and reiterates an Overweight rating on the shares. The company's Q4 results were essentially in line with the pre-release in mid-January but its 2020 guidance was below estimates, Halper tells investors in a research note. However, this was not too surprising given Health Insurance's intention to de-emphasize the IFP segment, says the analyst. He believes that while some investors will try to spin the guidance as negative, "the shift to Medicare is real."